Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

IGF2BP2 (Insulin-like growth factor 2 mRNA-binding protein 2) is a member of the IGF-II mRNA-binding protein family that post-transcriptionally regulates IGF2 during developmental stages.

Western Blot Analysis:
Representative lot data.
HepG2 cell lysate was probed with Anti-IGF2BP2, clone 5E10-3E1 (1:20,000 dilution).
Proteins were visualized using a Goat Anti-Mouse IgG secondary antibody conjugated to HRP and a chemiluminescence detection system.
Arrow indicates IGF2BP2 (~66 kDa).
Note: An uncharacterized band appears at ~50 kDa in some lysates.

General description

RIPAb+ antibodies are evaluated using the RNA Binding Protein Immunoprecipitation (RIP) assay. Each RIPAb+ antibody set includes a negative control antibody to ensure specificity of the RIP reaction and is verified for the co-immunoprecipitation of RNA associated specifically with the immunoprecipitated RNA-binding protein of interest. Where appropriate, the RIPAb+ set also includes quantitative RT-PCR control primers (RIP Primers) to biologically validate your IP results by successfully co-precipitating the specific RNA targets, such as messenger RNAs. The qPCR protocol and primer sequences are provided, allowing researchers to validate RIP protocols when using the antibody in their experimental context. If a target specific assay is not provided, the RIPAb+ kit is validated using an automated microfluidics-based assay by enrichment of detectable RNA over control immunoprecipitation.
IGF2BP2 (Insulin-like growth factor 2 mRNA-binding protein 2) is a member of the IGF-II mRNA-binding protein family that post-transcriptionally regulates IGF2 during developmental stages. IGF2BP1, 2, and 3 bind the UTR region of IGF2 transcripts, and are implicated in the transport of RNA targets, to enable protein synthesis at specific locations in the cytoplasm. Research has shown that the IGF2 gene may be involved in ovarian cancer.

Immunogen

Histidine-tagged recombinant protein corresponding to human IGF2BP2

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

MAGNA RIP is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Packaging

10 assays per set. Recommended use: 1.25 µg of antibody per RIP (dependent upon biological context).

Physical form

Format: Purified

Anti-IGF2BP2 (Mouse Monoclonal). One vial containing 12.5 µg protein G purified monoclonal in buffer containing 0.1 M Tris-glycine (pH 7.4), 150mM NaCl, 0.05% sodium azide before the addition of glycerol to 30%. Store at -20° C.
Concentration: 0.176 mg/mL
Normal mouse IgG. One vial containing 125 µg purified mouse IgG in 125 µL storage buffer containing 0.1% sodium azide. Store at -20°C.
RIP Primer IGF2. One vial containing 75 µL of 5 µM of each primer specific for human IGF2 mRNA. Store at -20°C.
FOR: GCG GCT TCT ACT TCA GCA G
REV: CAG GTG TCA TAT TGG AAG AAC

Quality

RNA Binding Protein Immunoprecipitation:
Representative lot data
RIP Lysate prepared from 293 cells (2 X 10E7 cell equivalents per IP) were subjected to immunoprecipitation using 1.25 µg of either a normal mouse IgG or 1.25 µg Anti-IGF2BP2 antibody and the Magna RIP^® RNA-Binding Protein Immunoprecipitation Kit (Cat. # 17-700).
Successful immunoprecipitation of IGF2BP2-associated RNA was verified by qPCR using RIP Primers IGF2, (Figure 1).
Please refer to the Magna RIP™ (Cat. # 17-700) or EZ-Magna RIP™ (Cat. # 17-701) protocol for experimental details.

Target description

~66 kDa